Perrigo Updates Note OfferPerrigo Co. (NYSE: PRGO) announced that, in connection with its offer to purchase for cash its 2.950% Notes due 2023, it has received the requisite consents to amend the indenture governing the notes.
Perrigo Confirms Filing For Generic Version Of AcanyaThe Allegan generic drugmaker and store brand health products producer Perrigo Co. (NYSE: PRGO) Wednesday announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application, of its filing.
Perrigo Shareholders Approve Elan AcquisitonThe generic prescription drug and store-brand health products maker Perrigo Co. (NYSE: PRGO) announced that its shareholders approved proposals related to its acuqisition of Ireland's Elan Corp. plc at a special meeting Monday.
Perrigo Announces FDA Final Approval For Generic Version Of Nitrolingual SprayPerrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.
Perrigo Sets Records For Quarterly, Annual Sales, ProfitsThe Allegan health and beauty products maker Perrigo Co. (Nasdaq: PRGO) reported record sales and net income for the fourth fiscal quarter and fiscal year ended June 29.
Perrigo Launching Three New ProductsThe Allegan generic drug maker will begin making two oils for dermatitis and a cancer drug.
Perrigo Sponsors Infant Nutrition Educational InitiativeThe health and beauty products maker Perrigo Co. (NYSE: PRGO) announced that its infant formula division, Perrigo Nutritionals, is working with the American Academy of Pediatrics to increase educational awareness around infant nutrition, health, and feeding options.
Perrigo Announces FDA Final Approval For Generic Equivalent To Cutivate LotionPerrigo Co. (NYSE: PRGO) Wednesday announced that it has received final approval for its abbreviated new drug application for fluticasone propionate lotion, 0.05%, the generic equivalent to Cutivate Lotion, 0.05%.
Perrigo Acquires Irish Competitor, Will Become Irish CompanyThe Allegan generic and store-brand health products maker Perrigo Co. announced early Monday that it would acquire Dublin, Ireland-based Elan Corp. plc for $8.6 billion (5.6 billion pounds).
Perrigo Gets Patent Challenge For Generic Axiron, FDA Approval For Generic Sanctura XRPerrigo Co. (Nasdaq: PRGO) announced that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for testosterone topical solution, the generic version of Axiron Topical Solution.
Perrigo To Transfer Common Stock Listing To NYSEPerrigo Co. (Nasdaq: PRGO) Thursday announced that it is transferring the listing of its U.S. traded common stock to the New York Stock Exchange from the Nasdaq Global Select Market.
Perrigo Closes Acquisition Of Pet Health Company VelceraPerrigo Co. (Nasdaq: PRGO) Monday announced that it has closed the acquisition of Velcera Inc., the Yardley, Pa.-based pet health products company, for $160 million in cash.